Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $1.68 per share which missed the analyst consensus estimate of $4.66 by 63.95 percent. This is a 37.31 percent decrease over earnings of $2.68 per share from the same period last year. The company reported quarterly sales of $897.84 million which missed the analyst consensus estimate of $985.39 million by 8.88 percent. This is a 0.46 percent decrease over sales of $901.98 million the same period last year.